Moayyedi, Paul <br/><br/>
Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial.  [electronic resource] 

 -  Gastroenterology  08 2019 
 - 403-412.e5 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1528-0012 
<br/><br/><label>Standard No.: </label>10.1053/j.gastro.2019.04.041  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Administration, Oral<br/>Aged<br/>Anticoagulants--administration & dosage<br/>Aspirin--administration & dosage<br/>Cardiovascular Diseases--prevention & control<br/>Dose-Response Relationship, Drug<br/>Double-Blind Method<br/>Drug Administration Schedule<br/>Drug Therapy, Combination--adverse effects<br/>Female<br/>Gastrointestinal Hemorrhage--chemically induced<br/>Humans<br/>Male<br/>Middle Aged<br/>Pantoprazole--administration & dosage<br/>Peptic Ulcer--chemically induced<br/>Proton Pump Inhibitors--administration & dosage<br/>Rivaroxaban--administration & dosage<br/>Treatment Outcome